🟢 Biovie is trading 7.8% up in pre-market ahead of Phase 2 study presentations

Biovie is trading at $1.25, up 7.76% pre-market; reporting does not link the rise to the announcement.

• On October 14, 2026, Biovie announced two Phase 2 presentations at the American Neurological Association meeting, October 17–20.
• Parkinson’s findings showed improvements across biomarkers and several clinical measures; the Long COVID trial did not reach statistical significance overall, with significant results limited to pre-specified subgroups.
• Risk-off markets followed hotter-than-expected inflation, but this does not explain Biovie’s move; trading-volume data was not provided.